AUS
NZ
UK
CA
USA
IND
Highlights
- PacBio and the National Cancer Centre of Singapore (NCCS) have entered a research collaboration aimed at advancing cancer research using cutting-edge sequencing technologies.
- The collaboration will combine PacBio's Onso short-read and Kinnex long-read sequencing platforms to explore cancer genomics, with a focus on cancers prevalent in Asia.
- This partnership highlights the potential for advanced multi-omics studies to improve precision oncology and create tailored diagnostic and treatment options for cancer patients.
In the Healthcare sector, PacBio has entered into a research collaboration agreement with the National Cancer Centre of Singapore (NCCS) to harness advanced sequencing technologies in the fight against cancer. PacBio, a leader in DNA sequencing, is working closely with NCCS to profile cancers that are particularly prevalent in Asia. This collaboration will leverage PacBio's expertise in sequencing technologies to drive new discoveries in cancer genomics and improve treatment outcomes.
Advanced Sequencing Technologies to Profile Asian Cancers
At the core of the partnership are PacBio (NASDAQ:PACB)’s state-of-the-art sequencing platforms, including the Onso short-read sequencing system and the Kinnex long-read sequencing kit. These platforms will be used to conduct comprehensive research on a wide range of cancers, with an emphasis on single-cell RNA sequencing, a technique that allows for precise profiling of individual cells within a tumor. The Onso platform, known for its high accuracy, will help detect mutations that are clinically relevant in cancer patients.
The collaboration aims to address the genomic complexities of cancers that are more prevalent in Asia, such as liver and gastric cancers. By understanding these cancers on a molecular level, researchers hope to uncover new insights into the biological mechanisms driving these diseases, potentially leading to improved diagnostic tools and personalized treatment strategies.
Combining Short-Read and Long-Read Sequencing for Precision Oncology
PacBio’s multi-omics approach integrates both short-read and long-read sequencing, offering a more complete picture of the cancer genome. The Onso platform will be used for short-read sequencing, providing detailed insights into genetic mutations, while PacBio’s Revio long-read platform will enable a deeper understanding of the structural variations and complex genomic regions that may contribute to cancer progression.
This collaboration will not only benefit cancer research in Singapore but also contribute to the global oncology community. By working with NCCS and integrating their sequencing technologies into the Cancer Discovery Hub, PacBio is supporting a vision of precision medicine, where treatments are tailored to each patient’s unique genetic profile.
